FDA approves 1st weekly basal insulin for Type 2 diabetes

Ella Jeffries / beckershospitalreview - The FDA has approved Novo Nordisk’s Awiqli (insulin icodec-abae), making it the first once-weekly basal insulin available in the U.S. for adults with Type 2 diabetes. Awiqli is indicated as an adjunct to diet and exercise and is intended to reduce injecti…

AI Summary: The FDA approved the first once‑weekly basal insulin for adults with Type 2 diabetes, providing an alternative to daily injections and aiming to improve adherence and glycemic control. Regulators based the decision on trials showing comparable efficacy and safety to daily basal insulins, potentially reshaping diabetes management.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 13 days

Denali drug receives accelerated approval for rare CNS indication / 2 months

Analysis finds anti-amyloid Alzheimer's drugs lack meaningful benefit / 6 wks

FDA approves Rocket Pharma gene therapy for ultra‑rare immune disorder / 2 months

FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 4 months

FDA rejects Corcept’s cortisol modulator triggering setback / 4 months

FDA approves Rucaparib for advanced prostate cancer / 5 months